LDL, VLDL, and Apolipoprotein B Management
For patients at moderate to high cardiovascular risk, target LDL-C <100 mg/dL (2.6 mmol/L) for high risk and <70 mg/dL (1.8 mmol/L) for very high risk, with apolipoprotein B <80 mg/dL for very high risk and <100 mg/dL for high risk; when triglycerides are ≥200 mg/dL (indicating elevated VLDL), target non-HDL-C 30 mg/dL above your LDL-C goal.
Risk Stratification Framework
Your treatment targets depend entirely on cardiovascular risk category:
Very High Risk (LDL-C goal <55-70 mg/dL)
- Established atherosclerotic cardiovascular disease (prior MI, stroke, PAD)
- Diabetes with target organ damage or multiple risk factors
- Familial hypercholesterolemia with ASCVD
- ApoB goal: <65-80 mg/dL 1, 2
- Non-HDL-C goal: <85-100 mg/dL 1, 3
High Risk (LDL-C goal <100 mg/dL)
- Diabetes without complications
- 10-year ASCVD risk ≥20%
- Severe single risk factor (LDL-C ≥190 mg/dL)
- ApoB goal: <80-100 mg/dL 1, 2
- Non-HDL-C goal: <130 mg/dL 3
Moderate Risk (LDL-C goal <130 mg/dL)
- Multiple risk factors with 10-year ASCVD risk 10-20%
- ApoB goal: <100 mg/dL 1
- Non-HDL-C goal: <130 mg/dL 1
Treatment Algorithm
Step 1: Initiate High-Intensity Statin
Start with a statin dose that achieves at least 30-40% LDL-C reduction 4, 3. For very high-risk patients, use high-intensity statins (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) 2.
Step 2: Add Ezetimibe if Goals Not Met
If LDL-C remains ≥70 mg/dL on maximally tolerated statin in very high-risk patients, add ezetimibe 5. This is a Class I recommendation with strong evidence. For high-risk patients, add ezetimibe if LDL-C ≥100 mg/dL despite statin therapy 5.
Step 3: Consider PCSK9 Inhibitors for Persistent Elevation
If LDL-C remains ≥100 mg/dL (2.6 mmol/L) on maximally tolerated statin plus ezetimibe in very high-risk patients, add a PCSK9 inhibitor 5. The European guidelines are more aggressive, recommending PCSK9 inhibitors as Class I for secondary prevention when goals aren't met 1.
Why Apolipoprotein B Matters
ApoB is superior to LDL-C for risk assessment because it directly measures the number of atherogenic particles, not just cholesterol content 6, 7, 8. Each atherogenic lipoprotein particle (VLDL, IDL, LDL, Lp(a)) contains exactly one apoB molecule, making it a direct particle count.
When ApoB and LDL-C Disagree
When discordance exists between LDL-C and apoB (which occurs frequently in clinical practice), cardiovascular risk tracks with apoB, not LDL-C 9, 8. This is particularly important in:
- Hypertriglyceridemia (elevated VLDL)
- Metabolic syndrome
- Diabetes
- Obesity
Even 2% discordance between apoB and LDL-P increases cardiovascular risk significantly (HR 1.1 for both MACE and CAD) 9.
Managing Elevated VLDL (Triglycerides)
When Triglycerides ≥200 mg/dL
Non-HDL-C becomes your secondary target, set 30 mg/dL above your LDL-C goal 4, 3. Non-HDL-C captures all atherogenic particles including VLDL remnants.
- Very high risk: non-HDL-C <85-100 mg/dL
- High risk: non-HDL-C <130 mg/dL
- Moderate risk: non-HDL-C <130 mg/dL
When Triglycerides >500 mg/dL
Start fibrate therapy immediately in addition to statins to prevent acute pancreatitis 3. This is a Class I recommendation.
For Triglycerides 200-499 mg/dL
After maximizing statin therapy, consider adding:
- Fibrate (fenofibrate preferred with statins) 3
- High-dose omega-3 fatty acids (icosapent ethyl 4g daily) 1
- Niacin (though less commonly used due to tolerability) 3
Critical Pitfalls to Avoid
Do not rely solely on LDL-C in patients with elevated triglycerides. When triglycerides are elevated, LDL-C underestimates atherogenic particle burden because VLDL remnants are not captured. Use non-HDL-C or apoB instead 10, 6.
Do not assume LDL-C <100 mg/dL means adequate treatment in very high-risk patients. The 2022 BMJ guideline and European guidelines support treating to LDL-C <70 mg/dL or even <55 mg/dL in this population 5, 1.
Do not delay adding ezetimibe. It's inexpensive, well-tolerated, and provides an additional 15-20% LDL-C reduction. The evidence strongly supports its use when statins alone don't achieve goals 5.
Monitoring Strategy
Recheck lipid panel 4-12 weeks after initiating or adjusting therapy 3. If available, measure apoB alongside standard lipids—it provides superior risk stratification both before and during treatment 8.
For patients on maximally tolerated statin plus ezetimibe who remain above goal, measure apoB to guide PCSK9 inhibitor decisions. If apoB remains >80 mg/dL in very high-risk patients despite combination therapy, PCSK9 inhibitor therapy is strongly justified 5, 1.
The evidence consistently shows that achieving lower is better for LDL-C, non-HDL-C, and apoB in reducing cardiovascular events, with the most aggressive targets reserved for those at highest absolute risk who stand to benefit most 5, 1, 2.